[3]Chen H, Gui X, Zhou Z, et al. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy. Breast. 2024 Jun;75:103733.[4]Allison KH, Hammond MEH, Dowsett...
Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisibMethods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.Mika K. Derynck...
Background The Society of Surgical Oncology introduced guidance discouraging routine axillary staging in women 70 years or older with invasive, clinically node negative, hormone-receptor positive breast cancer. Due to concerns this could result in patients missing necessary treatment, researchers from the...
参考文献: 1. Tarantino P,Hamilton E, Tolaney S M, et al. HER2-Low Breast Cancer: Pathological andClinical Landscape[J]. Journal of Clinical Oncology, 2020, 38(17): 1951-1962. 2. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient...
1. Tarantino P,Hamilton E, Tolaney S M, et al. HER2-Low Breast Cancer: Pathological andClinical Landscape[J]. Journal of Clinical Oncology, 2020, 38(17): 1951-1962. 2. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from...
Association of hormone-sensitive miRNAs expression with main clinicopathologic characteristics of ER/PR-positive breast cancerdoi:10.1016/j.annonc.2020.08.271T. KalininaV. KononchukE. AlekseenokL. GulyaevaAnnals of Oncology
注释: 1. Tarantino P,Hamilton E, Tolaney S M, et al. HER2-Low Breast Cancer: Pathological andClinical Landscape[J]. Journal of Clinical Oncology, 2020, 38(17): 1951-1962. 2. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled ysis of individual patient data...
[6] Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a deive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 201...
[2] Knauer M, Cardoso F, Wesseling J, et al. Identification of a Low-Risk Subgroup of HER2-Positive Breast Cancer by the 70-Gene Prognosis Signature. British Journal of Cancer. 2010(103): 1788-1793. [3] Pinhel ...
(2014). Passive smoking exposure from partners as a risk factor for ER+/PR + double positive breast cancer in never-smoking Chinese urban women: a ... Jian-hua,Tong,Zhi,... - 《Plos One》 被引量: 9发表: 2014年 Passive Smoking Exposure from Partners as a Risk Factor for ER+/PR+ ...